Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 57, 2022 - Issue 9
Submit an article Journal homepage
691
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Risk of progression in Barrett’s esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland

Heikki Huhtaa Surgery Research Unit, Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland;b Surgery Research Unit, Oulu University Hospital, Oulu, FinlandCorrespondence[email protected]
View further author information
,
Jukka Melkkoc Department of Pathology, Oulu University Hospital, Oulu, FinlandView further author information
,
Teijo Kuopiod Department of Pathology, Jyväskylä Central Hospital, Jyväskylä, FinlandView further author information
,
Tuomo J. Karttunena Surgery Research Unit, Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, FinlandView further author information
&
Olli Helminena Surgery Research Unit, Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland;b Surgery Research Unit, Oulu University Hospital, Oulu, FinlandView further author information
Pages 1024-1029 | Received 24 Jan 2022, Accepted 01 Apr 2022, Published online: 21 Apr 2022

References

  • Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149(2):302–317.e301.
  • Schlottmann F, Patti MG. Current concepts in treatment of Barrett's esophagus with and without dysplasia. J Gastrointest Surg. 2017;21(8):1354–1360.
  • Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2006;55(12):1810–1820.
  • Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–1530.
  • Duits LC, Phoa KN, Curvers WL, et al. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–706.
  • Krishnamoorthi R, Lewis JT, Krishna M, et al. Predictors of progression in Barrett's esophagus with low-grade dysplasia: results from a multicenter prospective BE registry. Am J Gastroenterol. 2017;112(6):867–873.
  • Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy. 2017;49(02):191–198.
  • Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett's low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112(6):849–865.
  • Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol. 2004;39(12):1175–1179.
  • Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365(15):1375–1383.
  • Naini BV, Souza RF, Odze RD. Barrett's esophagus: a comprehensive and contemporary review for pathologists. Am J Surg Pathol. 2016;40(5):e45–e66.
  • Kinra P, Gahlot GPS, Yadav R, et al. Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa. Pathol Res Pract. 2018;214(7):993–999.
  • Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47(2):251–255.
  • Pech O, Vieth M, Schmitz D, et al. Conclusions from the histological diagnosis of low-grade intraepithelial neoplasia in Barrett's oesophagus. Scand J Gastroenterol. 2007;42(6):682–688.
  • Kerkhof M, van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology. 2007;50(7):920–927.
  • Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32(4):368–378.
  • Duits LC, van der Wel MJ, Cotton CC, et al. Patients with Barrett's esophagus and confirmed persistent low-grade dysplasia are at increased risk for progression to Neoplasia. Gastroenterology. 2017;152(5):993–1001.e1001.
  • Skacel M, Petras RE, Rybicki LA, et al. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol. 2002;97(10):2508–2513.
  • Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut. 2013;62(12):1676–1683.
  • Janmaat VT, van Olphen SH, Biermann KE, et al. Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: a systematic review and Meta-analysis. PLOS One. 2017;12(10):e0186305.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.